Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.

R, Fleischmann; M, Schiff; der Heijde D, van; C, Ramos-Remus; A, Spindler; M, Stanislav; CA, Zerbini; S, Gurbuz; C, Dickson; Bono S, de; D, Schlichting; S, Beattie; WL, Kuo; T, Rooney; W, Macias; T, Takeuchi

doi:10.1002/art.39953

Public

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.

Shared by NobleBlocks on Mar 1, 2017 • 12:00 AM UTC

Authors:

Fleischmann R

Schiff M

van der Heijde D

Abstract

<h4>Objective</h4>We undertook this phase III study to evaluate baricitinib, an orally administered JAK-1/JAK-2 inhibitor, as monotherapy or combined with methotrexate (MTX) compared to MTX monotherapy in patients with active rheumatoid arthritis (RA) who had received no or minimal conventional synt...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!